180 Life Sciences Corp. – NASDAQ:ATNF

Add to watchlist

$7.3

+5.14

+239.52%

Market closed

Open in about 7 hours

+0.94%

month

+0.94%

quarter

+933.65%

year

Market Cap	3.61M
Enterprise value	N/A

P/E	-0.07
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	0.09
PEG ratio	N/A
EPS	-41.58

Revenue	N/A
EBITDA	-10.65M
Income	-16.24M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

180 Life Sciences Corp. (NASDAQ:ATNF): Profit margin
Jun 2023	0	-3.68M
Sep 2023	0	-10.26M
Dec 2023	166.03K	-1.22M	-739.09%
Mar 2024	0	-1.06M

180 Life Sciences Corp. Financials Estimate

Q Y

180 Life Sciences Corp. (NASDAQ:ATNF): Analyst Estimates
2025	16.64M	-21.60M	-129.84%
2026	30.41M	21.60M	71.05%

Analysts Price target
Financials & Ratios estimates

180 Life Sciences Corp. (NASDAQ:ATNF): Debt to assets
Jun 2023	13666714	6.95M	50.86%
Sep 2023	4958085	5.10M	103.01%
Dec 2023	5259476	5.38M	102.43%
Mar 2024	3441740	4.39M	127.73%

180 Life Sciences Corp. (NASDAQ:ATNF): Cash Flow
Jun 2023	-3.11M	640.39K	2.46M
Sep 2023	-1.77M	-4.85M	2.44M
Dec 2023	-2.16M	4.21M	1.46M
Mar 2024	-1.03M	0	-264.39K

180 Life Sciences Corp. alternative data

180 Life Sciences Corp.
Employees

180 Life Sciences Corp. (NASDAQ:ATNF): Employee count
Aug 2023	5
Sep 2023	5
Oct 2023	5
Nov 2023	5
Dec 2023	5
Jan 2024	5
Feb 2024	5
Mar 2024	5
Apr 2024	5
May 2024	4
Jun 2024	4
Jul 2024	4

180 Life Sciences Corp.
Hedge Funds Holdings Q1 2023

6.75% -2.13%

of ATNF is owned by hedge funds

7 -9

hedge funds hold ATNF stock

132.18K -41.66K

shares is hold by hedge funds

ATNF hedge funds holdings changes

180 Life Sciences Corp.
Insider Trading

180 Life Sciences Corp. (NASDAQ:ATNF): Insider trades (number of shares)
Period	Buy	Sel
May 2023	77244	0
Jun 2023	18000	0
Dec 2023	25000	25000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	15 Dec 2023	FELDMANN MARC director director	Common Stock	25,000	$0.19	$4,700
Purchase	15 Dec 2023	WOODY JAMES N. director, officer..	Common Stock	25,000	$0.19	$4,700
Purchase	1 Jun 2023	STEINMAN LAWRENCE director director	Common Stock	18,000	$1.23	$22,068
Purchase	31 May 2023	MCGOVERN JR. DONALD A. director director	Common Stock	10,000	$1.15	$11,470
Purchase	19 May 2023	MCGOVERN JR. DONALD A. director director	Common Stock	5,000	$1.16	$5,800
Purchase	18 May 2023	MARRONE PAMELA G director	Common Stock	7,082	$1.06	$7,507
Purchase	18 May 2023	PAMIR OZAN officer: CFO officer: CFO	Common Stock	5,162	$1.01	$5,214
Purchase	18 May 2023	MCGOVERN JR. DONALD A. director director	Common Stock	10,000	$1.05	$10,500
Purchase	18 May 2023	WOODY JAMES N. director, officer..	Common Stock	40,000	$1.03	$41,200
Purchase	16 Dec 2021	VU QUAN ANH officer: COO / Chief Business Officer officer: COO / Chief Business O..	Common Stock	8,000	$3.98	$31,840

ATNF insider trading transactions

180 Life Sciences Corp.
Executives

Insider	Age	Compensation
Dr. Jonathan B. Rothbard Ph.D. (1952) Chief Scientific Officer	73	$333,970
Mr. Ozan Pamir C.F.A. (1992) Interim Chief Financial Officer & Sec.	33	$299,750
Dr. James N. Woody M.D., Ph.D. (1942) Chief Executive Officer & Director	83	$265,170

180 Life Sciences Corp.
Latest News

Friday, 27 December 2024
09:00	180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules	accesswire.com
Thursday, 12 December 2024
08:00	180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules	accesswire.com
Wednesday, 4 December 2024
08:00	180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors	accesswire.com
Tuesday, 29 October 2024
08:00	180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors	accesswire.com
Wednesday, 16 October 2024
08:00	180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform	accesswire.com
Wednesday, 9 October 2024
08:30	180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector	accesswire.com
Thursday, 3 October 2024
08:30	180 Life Sciences Corp. - Corporate Updates	accesswire.com
Thursday, 12 September 2024
16:15	180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer	globenewswire.com
Tuesday, 30 July 2024
08:00	180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake	globenewswire.com
Tuesday, 2 July 2024
08:30	180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements	globenewswire.com
Thursday, 14 March 2024
08:30	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement	globenewswire.com
Monday, 26 February 2024
07:00	180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan	globenewswire.com
Monday, 4 December 2023
09:00	180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives	globenewswire.com
Tuesday, 28 November 2023
09:00	180 Life Sciences Announces Review of Strategic Alternatives	globenewswire.com
Monday, 14 August 2023
16:29	180 Life Sciences Corp. Announces Closing of $3 Million Public Offering	globenewswire.com
Thursday, 10 August 2023
08:46	180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering	globenewswire.com
Wednesday, 9 August 2023
08:06	Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?	InvestorPlace
Sunday, 21 May 2023
06:00	Penny Stock Investing, 3 High-Growth Industries to Watch	PennyStocks
Friday, 19 May 2023
12:57	5 Top Penny Stocks To Watch Today; Time To Buy?	PennyStocks
Monday, 9 January 2023
06:00	Using News to Find Penny Stocks to Buy: 3 Tips	PennyStocks
Friday, 6 January 2023
12:27	Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch	PennyStocks
Saturday, 31 December 2022
11:00	3 Essential Strategies for Penny Stocks Trading in 2023	PennyStocks
Saturday, 24 December 2022
16:27	The 7 Most Sold-Off Stocks of 2022	InvestorPlace
Monday, 19 December 2022
08:43	180 Life Sciences (ATNF) Stock: 1-For-20 Reverse Split Goes Into Effect	Pulse2
Wednesday, 15 June 2022
08:28	Why 180 Life Sciences Shares Are Plunging Today	Benzinga
Monday, 31 January 2022
08:31	180 Life Sciences (ATNF) Stock: Why The Price Jumped Up Today	Pulse2
Tuesday, 28 December 2021
11:00	180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022	GlobeNewsWire
Friday, 10 December 2021
11:06	4 Penny Stocks To Buy For Under $5 Before 2022	PennyStocks
Thursday, 18 November 2021
15:33	180 Life Sciences (ATNF) Stock: Why The Price Jumped Today	Pulse2
08:15	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of 180 Life Sciences Corp. stock today?

One share of 180 Life Sciences Corp. stock can currently be purchased for approximately $7.3.
When is 180 Life Sciences Corp.'s next earnings date?

Unfortunately, 180 Life Sciences Corp.'s (ATNF) next earnings date is currently unknown.
Does 180 Life Sciences Corp. pay dividends?

No, 180 Life Sciences Corp. does not pay dividends.
How much money does 180 Life Sciences Corp. make?

180 Life Sciences Corp. has a market capitalization of 3.61M.
What is 180 Life Sciences Corp.'s stock symbol?

180 Life Sciences Corp. is traded on the NASDAQ under the ticker symbol "ATNF".
What is 180 Life Sciences Corp.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of 180 Life Sciences Corp.?

Shares of 180 Life Sciences Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are 180 Life Sciences Corp.'s key executives?
180 Life Sciences Corp.'s management team includes the following people:
- Dr. Jonathan B. Rothbard Ph.D. Chief Scientific Officer(age: 73, pay: $333,970)
- Mr. Ozan Pamir C.F.A. Interim Chief Financial Officer & Sec.(age: 33, pay: $299,750)
- Dr. James N. Woody M.D., Ph.D. Chief Executive Officer & Director(age: 83, pay: $265,170)
How many employees does 180 Life Sciences Corp. have?

As Jul 2024, 180 Life Sciences Corp. employs 4 workers, which is 20% less then previous quarter.
When 180 Life Sciences Corp. went public?

180 Life Sciences Corp. is publicly traded company for more then 8 years since IPO on 27 Jun 2017.
What is 180 Life Sciences Corp.'s official website?

The official website for 180 Life Sciences Corp. is 180lifesciences.com.
Where are 180 Life Sciences Corp.'s headquarters?

180 Life Sciences Corp. is headquartered at Building 4, Palo Alto, CA.
How can i contact 180 Life Sciences Corp.?

180 Life Sciences Corp.'s mailing address is Building 4, Palo Alto, CA and company can be reached via phone at +65 05070669.

180 Life Sciences Corp.

180lifesciences.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

+65 05070669

Building 4
Palo Alto, CA 94306

CIK: 0001690080
ISIN: US68236V3024
CUSIP: 68236V104